These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 34806305)

  • 1. Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review.
    Derking R; Sanders RW
    J Int AIDS Soc; 2021 Nov; 24 Suppl 7(Suppl 7):e25797. PubMed ID: 34806305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers.
    Schorcht A; van den Kerkhof TLGM; Cottrell CA; Allen JD; Torres JL; Behrens AJ; Schermer EE; Burger JA; de Taeye SW; Torrents de la Peña A; Bontjer I; Gumbs S; Ozorowski G; LaBranche CC; de Val N; Yasmeen A; Klasse PJ; Montefiori DC; Moore JP; Schuitemaker H; Crispin M; van Gils MJ; Ward AB; Sanders RW
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.
    Ringe RP; Pugach P; Cottrell CA; LaBranche CC; Seabright GE; Ketas TJ; Ozorowski G; Kumar S; Schorcht A; van Gils MJ; Crispin M; Montefiori DC; Wilson IA; Ward AB; Sanders RW; Klasse PJ; Moore JP
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
    Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
    J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
    Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
    J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination.
    Dingens AS; Pratap P; Malone K; Hilton SK; Ketas T; Cottrell CA; Overbaugh J; Moore JP; Klasse PJ; Ward AB; Bloom JD
    Elife; 2021 Jan; 10():. PubMed ID: 33438580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination.
    Torrents de la Peña A; de Taeye SW; Sliepen K; LaBranche CC; Burger JA; Schermer EE; Montefiori DC; Moore JP; Klasse PJ; Sanders RW
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29367243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.
    Pugach P; Ozorowski G; Cupo A; Ringe R; Yasmeen A; de Val N; Derking R; Kim HJ; Korzun J; Golabek M; de Los Reyes K; Ketas TJ; Julien JP; Burton DR; Wilson IA; Sanders RW; Klasse PJ; Ward AB; Moore JP
    J Virol; 2015 Mar; 89(6):3380-95. PubMed ID: 25589637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HIV-1 envelope glycoprotein structure: nailing down a moving target.
    Ward AB; Wilson IA
    Immunol Rev; 2017 Jan; 275(1):21-32. PubMed ID: 28133813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers
    Ozorowski G; Cupo A; Golabek M; LoPiccolo M; Ketas TA; Cavallary M; Cottrell CA; Klasse PJ; Ward AB; Moore JP
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29669838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.
    Sanders RW; Derking R; Cupo A; Julien JP; Yasmeen A; de Val N; Kim HJ; Blattner C; de la Peña AT; Korzun J; Golabek M; de Los Reyes K; Ketas TJ; van Gils MJ; King CR; Wilson IA; Ward AB; Klasse PJ; Moore JP
    PLoS Pathog; 2013 Sep; 9(9):e1003618. PubMed ID: 24068931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.
    Gach JS; Mara KJV; LaBranche CC; van Gils MJ; McCoy LE; Klasse PJ; Montefiori DC; Sanders RW; Moore JP; Forthal DN
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31375582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins.
    Schiffner T; Pallesen J; Russell RA; Dodd J; de Val N; LaBranche CC; Montefiori D; Tomaras GD; Shen X; Harris SL; Moghaddam AE; Kalyuzhniy O; Sanders RW; McCoy LE; Moore JP; Ward AB; Sattentau QJ
    PLoS Pathog; 2018 May; 14(5):e1006986. PubMed ID: 29746590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers.
    Ringe RP; Ozorowski G; Rantalainen K; Struwe WB; Matthews K; Torres JL; Yasmeen A; Cottrell CA; Ketas TJ; LaBranche CC; Montefiori DC; Cupo A; Crispin M; Wilson IA; Ward AB; Sanders RW; Klasse PJ; Moore JP
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.
    Medina-Ramírez M; Sanders RW; Sattentau QJ
    Curr Opin HIV AIDS; 2017 May; 12(3):241-249. PubMed ID: 28422788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles.
    Kumar S; Lin X; Ngo T; Shapero B; Sou C; Allen JD; Copps J; Zhang L; Ozorowski G; He L; Crispin M; Ward AB; Wilson IA; Zhu J
    mBio; 2021 Jun; 12(3):e0042921. PubMed ID: 34156262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers.
    de Taeye SW; Go EP; Sliepen K; de la Peña AT; Badal K; Medina-Ramírez M; Lee WH; Desaire H; Wilson IA; Moore JP; Ward AB; Sanders RW
    J Biol Chem; 2019 Apr; 294(14):5616-5631. PubMed ID: 30728245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
    Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
    J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope-Independent Purification of Native-Like Envelope Trimers from Diverse HIV-1 Isolates.
    Verkerke HP; Williams JA; Guttman M; Simonich CA; Liang Y; Filipavicius M; Hu SL; Overbaugh J; Lee KK
    J Virol; 2016 Oct; 90(20):9471-82. PubMed ID: 27512064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.